Beacon Hill Wealth Management’s Akebia Therapeutics AKBA Stock Holding History

Beacon Hill Wealth Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.8K	Buy	+20,000	New	+$23.8K	0.02%	27

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Beacon Hill Wealth Management's AKBA Position: Q2 2026 in Review

Beacon Hill Wealth Management opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 20,000 shares worth $22.8K. The stake represents 0.02% of the portfolio and ranks #27 among its holdings.

155 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Beacon Hill Wealth Management held 20,000 shares of Akebia Therapeutics worth $22.8K as of Q2 2026.
Akebia Therapeutics was a new Beacon Hill Wealth Management position in Q2 2026.
Akebia Therapeutics made up 0.02% of Beacon Hill Wealth Management's portfolio in Q2 2026, its #27 holding.
155 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Beacon Hill Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.